Page 1144 - Hematology_ Basic Principles and Practice ( PDFDrive )

1004.e6 Part XII Hemostasis and Thrombosis

228. Zipursky A: The treatment of children with acute megakaryoblastic 250. Sekhar M, Prentice HG, Popat U, et al: Idiopathic myelofibrosis in
leukemia who have Down syndrome. J Pediatr Hematol Oncol 8:10, children. Br J Haematol 93:394, 1996.
1996. 251. Reilly JT: Idiopathic myelofibrosis: pathogenesis to treatment. Hematol
229. Massey GV, Zipursky A, Chang MN, et al: A prospective study of Oncol 24:56, 2006.
the natural history of transient leukemia (TL) in neonates with Down 252. Chou JM, Li CY, Tefferi A: Bone marrow immunohistochemical
syndrome (DS): Children’s Oncology Group (COG) study POG-9481. studies of angiogenic cytokines and their receptors in myelofibrosis
Blood 107:4606, 2006. with myeloid metaplasia. Leuk Res 27:499, 2003.
230. Sceats DJ, Baitlon D: Primary thrombocythemia in a child. Clin Pediatr 253. Tefferi A, Silverstein MN, Noel P: Agnogenic myeloid metaplasia.
(Phila) 19:298, 1980. Semin Oncol 22:327, 1995.
231. Randi ML, Putti MC, Scapin M, et al: Pediatric patients with essential 254. Barosi G, Ambrosetti A, Buratti A, et al: Splenectomy for patients
thrombocythemia are mostly polyclonal and V617FJAK2 negative. with myelofibrosis with myeloid metaplasia: pretreatment variables and
Blood 108:3600, 2006. outcome prediction. Leukemia 7:200, 1993.
232. El-Moneim AA, Kratz CP, Boll S, et al: Essential versus reactive throm- 255. Silverstein MN, ReMine WH: Splenectomy in myeloid metaplasia.
bocythemia in children: retrospective analyses of 12 cases. Pediatr Blood Blood 53:515, 1979.
Cancer 49:52, 2007. 256. Tefferi A, Mesa RA, Gray LA, et al: Phase 2 trial of imatinib mesylate
233. Hasle H: Incidence of essential thrombocythaemia in children. Br J in myelofibrosis with myeloid metaplasia. Blood 99:3854, 2002.
Haematol 110:751, 2000. 257. Cortes J, Giles F, O’Brien S, et al: Results of imatinib mesylate therapy
234. Dame C, Sutor AH: Primary and secondary thrombocytosis in child- in patients with refractory or recurrent acute myeloid leukemia,
hood. Br J Haematol 129:165, 2005. high-risk myelodysplastic syndrome, and myeloproliferative disorders.
235. Campbell PJ, Scott LM, Buck G, et al: Definition of subtypes of Cancer 97:2760, 2003.
essential thrombocythaemia and relation to polycythaemia vera based 258. Elliott MA, Mesa RA, Li CY, et al: Thalidomide treatment in myelofi-
on JAK2 V617F mutation status: a prospective study. Lancet 366:1945, brosis with myeloid metaplasia. Br J Haematol 117:288, 2002.
2005. 259. Marchetti M, Barosi G, Balestri F, et al: Low-dose thalidomide ame-
236. Klampfl T, Gisslinger H, Harutyunyan AS, et al: Somatic mutations of liorates cytopenias and splenomegaly in myelofibrosis with myeloid
calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379, metaplasia: a phase II trial. J Clin Oncol 22:424, 2004.
2013. 260. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy on
237. Teofili L, Giona F, Martini M, et al: Markers of myeloproliferative dis- INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J
eases in childhood polycythemia vera and essential thrombocythemia. Med 363:1117, 2010.
J Clin Oncol 25:1048, 2007. 261. Geyer HL, Mesa RA: Therapy for myeloproliferative neoplasms: when,
238. Marty C, Saint-Martin C, Pecquet C, et al: Germ-line JAK2 mutations which agent, and how? Blood 124:3529, 2014.
in the kinase domain are responsible for hereditary thrombocytosis and 262. Guardiola P, Esperou H, Cazals-Hatem D, et al: Allogeneic bone
are resistant to JAK2 and HSP90 inhibitors. Blood 123:1372, 2014. marrow transplantation for agnogenic myeloid metaplasia. French
239. Hoagland HC, Silverstein MN: Primary thrombocythemia in the Society of Bone Marrow Transplantation. Br J Haematol 98:1004, 1997.
young patient. Mayo Clin Proc 53:578, 1978. 263. Shanavas M, Messner HA, Atenafu EG, et al: Allogeneic hematopoietic
240. Tartaglia AP, Goldberg JD, Berk PD, et al: Adverse effects of antiag- cell transplantation for myelofibrosis using fludarabine-, intravenous
gregating platelet therapy in the treatment of polycythemia vera. Semin busulfan- and low-dose TBI-based conditioning. Bone Marrow Trans-
Hematol 23:172, 1986. plant 49:1162, 2014.
241. Rozman C, Giralt M, Feliu E, et al: Life expectancy of patients with 264. Claudiani S, Marktel S, Piemontese S, et al: Treosulfan based reduced
chronic nonleukemic myeloproliferative disorders. Cancer 67:2658, toxicity conditioning followed by allogeneic stem cell transplantation in
1991. patients with myelofibrosis. Hematol Oncol 2015; Epub ahead of print.
242. Finazzi G, Carobbio A, Thiele J, et al: Incidence and risk factors for 265. Osgood EE: Polycythemia vera: age relationships and survival. Blood
bleeding in 1104 patients with essential thrombocythemia or prefibrotic 26:243, 1965.
myelofibrosis diagnosed according to the 2008 WHO criteria. Leuke- 266. Bento C, Percy MJ, Gardie B, et al: Genetic basis of congenital eryth-
mia 26:716, 2012. rocytosis: mutation update and online databases. Hum Mutat 35:15,
243. Carobbio A, Thiele J, Passamonti F, et al: Risk factors for arterial and 2014.
venous thrombosis in WHO-defined essential thrombocythemia: an 267. Spivak JL: The chronic myeloproliferative disorders: clonality and
international study of 891 patients. Blood 117:5857, 2011. clinical heterogeneity. Semin Hematol 41:1, 2004.
244. Gilbert HS: Historical perspective on the treatment of essential throm- 268. Zhao R, Xing S, Li Z, et al: Identification of an acquired JAK2 muta-
bocythemia and polycythemia vera. Semin Hematol 36:19, 1999. tion in polycythemia vera. J Biol Chem 280:22788, 2005.
245. Barbui T, Barosi G, Grossi A, et al: Practice guidelines for the therapy 269. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the
of essential thrombocythemia. A statement from the Italian Society tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet
of Hematology, the Italian Society of Experimental Hematology and 365:1054, 2005.
the Italian Group for Bone Marrow Transplantation. Haematologica 270. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation
89:215, 2004. leading to constitutive signalling causes polycythaemia vera. Nature
246. Giles FJ, Singer CR, Gray AG, et al: Alpha-interferon therapy for 434:1144, 2005.
essential thrombocythaemia. Lancet 2:70, 1988. 271. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function muta-
247. Anderson JE, Sale G, Appelbaum FR, et al: Allogeneic marrow trans- tion of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779,
plantation for primary myelofibrosis and myelofibrosis secondary to 2005.
polycythaemia vera or essential thrombocytosis. Br J Haematol 98:1010, 272. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the
1997. tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia,
248. Kerbauy DM, Gooley TA, Sale GE, et al: Hematopoietic cell trans- and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387, 2005.
plantation as curative therapy for idiopathic myelofibrosis, advanced 273. Passamonti F, Elena C, Schnittger S, et al: Molecular and clinical
polycythemia vera, and essential thrombocythemia. Biol Blood Marrow features of the myeloproliferative neoplasm associated with JAK2 exon
Transplant 13:355, 2007. 12 mutations. Blood 117:2813, 2011.
249. Lussana F, Rambaldi A, Finazzi MC, et al: Allogeneic hematopoietic 274. Temerinac S, Klippel S, Strunck E, et al: Cloning of PRV-1, a novel
stem cell transplantation in patients with polycythemia vera or essen- member of the uPAR receptor superfamily, which is overexpressed in
tial thrombocythemia transformed to myelofibrosis or acute myeloid polycythemia rubra vera. Blood 95:2569, 2000.
leukemia: a report from the MPN Subcommittee of the Chronic 275. Teofili L, Pierconti F, Di Febo A, et al: The expression pattern of
Malignancies Working Party of the European Group for Blood and c-mpl in megakaryocytes correlates with thrombotic risk in essential
Marrow Transplantation. Haematologica 99:916, 2014. thrombocythemia. Blood 100:714, 2002.